Neurodegenerative Diseases
An Introduction to Neurodegenerative Diseases
Huntington’s Disease (HD) is a rare, incurable, inherited and ultimately fatal neurodegenerative disorder characterised by chorea, ataxia, dysphagia, cognitive and behavioural changes. Current therapies offer only symptomatic relief, and many are associated with significant side effects, though pridopidine, a sigma-1-receptor (S1R) agonist has shown potential for both symptomatic treatment and disease modifying effects in HD. Advances in our understanding of the pathogenesis of HD have highlighted the importance of DNA repair genes, and novel approaches, such as the antisense therapy tominersen and the oral agent branaplam, are targeting the mutant huntingtin (mHTT) protein and the HTT gene. However, no disease-modifying therapy is yet approved for HD.
Our supporting partners do not constitute an endorsement of the content on this page.
Recent omaveloxolone updates include progress in the phase 3 BRAVE study, development of a liquid-ready formulation and evolving reimbursement discussions across multiple regions Phase 3 BRAVE study advances pediatric development in Friedreich’s ataxia Biogen is continuing to expand the clinical development ...
Leading experts share their perspectives on the most important therapeutic and treatment updates at AAN 2026 and discuss how these findings may shape the future of neurologic care At American Academy of Neurology (AAN) Annual Meeting, Chicago, IL, USA, April 18–22, 2026, major ...
Emerging data from AAN 2026 across neuroimmunology, epilepsy, neuromuscular disease, movement disorders and neuroinfectious disease highlighted the continued evolution of neurology toward more precise, personalized and mechanism-driven care. The American Academy of Neurology (AAN) Annual Meeting, Chicago, IL, USA, from April 18–22, 2026, ...
Findings from AAN 2026 highlight a potential “survival paradox” associated with GLP-1 analogue use in older adults with diabetes At American Academy of Neurology 2026, Isaac Thorman (New York Medical College, Valhalla, NY, USA) presented new real-world data exploring the relationship between ...
New findings highlight the importance of functional antiviral immunity, beyond lymphocyte expansion alone, in progressive multifocal leukoencephalopathy. At American Academy of Neurology 2026, Dr Yair Mina (Staff Clinician, Experimental Immunotherapeutics Unit, National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, MD, ...
The late-breaking science sessions at AAN Annual Meeting 2026, Chicago, IL, USA brought together a wide range of pivotal and practice-shaping data spanning rare disease, neuroimmunology, headache, epilepsy, neurodegeneration and neuromuscular medicine. Several presentations reported positive phase III findings, while others ...
Six key oral presentations from this year’s ADI meeting on diagnosis, therapies and innovation in care Conference coverage | Held from 14–16 April, the 37th Global Conference of Alzheimer’s Disease International (ADI), Lyon, France, brought together global expertise and lived ...
New Phase 2b data highlight the potential of targeting synaptic dysfunction to slow disease progression in dementia with Lewy bodies Dementia with Lewy bodies (DLB) remains an area of high unmet need, with no approved disease-modifying therapies and significant clinical ...
We often focus on clinical excellence, but spend less time developing broader skills that could help us better lead with purpose and build more fulfilling, impactful careers. In this episode, part of a mini-series in partnership with LEADderm, Dr Jennifer Soung and Denise Mann explore how clinicians can engage with the media to educate, empower and extend their impact beyond the clinic.
Learn about the benefits and limitations of healthcare claims data in Friedreich ataxia.
It is my pleasure to introduce the 2025 of touchREVIEWS in Neurology, which brings together an exceptional collection of reviews, original research and congress highlights that reflect the continued evolution of neurological science and clinical innovation. This issue opens with Jelle ...
Huntington’s disease (HD) is a fatal, autosomal-dominant, neurodegenerative disorder caused by a cytosine–adenine–guanine (CAG) trinucleotide repeat expansion in the huntingtin (HTT) gene, located on chromosome 4p16.3. When this repeat exceeds 36 units, it leads to the synthesis of ...
In our inaugural touchNEUROLOGY Future Leaders 2025 campaign, we celebrate the next generation of neurologists, rising stars shaping the future of clinical practice, research, and education across neurological specialties.
The Phase 1/2 study of AMT-130, the first in-human gene therapy designed to slow the course of Huntington’s disease (HD), has announced positive topline results from its pivotal trial.1 The data provide hope that a intrastriatal adeno-associated virus (AVV)-based ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
